Loading
A phase 3 trial of Pucotenlimab, run by Taizhou Hanzhong biomedical co. LTD in colorectal cancer, active.
A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer is a phase 3 interventional study registered as NCT05652894 by Taizhou Hanzhong biomedical co. LTD, with 190 participants planned, started 2023-02-28. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pucotenlimab, Immune checkpoint inhibitors.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer, Immune checkpoint inhibitors.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer, Immune checkpoint inhibitors.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer, Immune checkpoint inhibitors.
Shares Pucotenlimab, Immune checkpoint inhibitors.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer, Immune checkpoint inhibitors.
Shares Pucotenlimab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/